Abstract
Importance Understanding the pathogenic mechanisms of Fuchs endothelial corneal dystrophy (FECD) is essential for developing gene-targeted therapies.
Objective To investigate associations between demographic data and age at first keratoplasty in a large genetically refined FECD cohort.
Design, Setting, and Participants This retrospective cohort study recruited 894 individuals with FECD at Moorfields Eye Hospital (London) and General University Hospital (Prague). Ancestry was inferred from genome-wide SNP array data. CTG18.1 status was determined by short tandem repeat and/or triplet-primed PCR. One or more expanded alleles (≥50 repeats) were classified as expansion-positive (Exp+). Expansion-negative (Exp-) cases were whole exome sequenced.
Main Outcome(s) and Measure(s) Association between variants in FECD-associated genes, demographic data and age at first keratoplasty.
Results Within the total cohort (n=894), 77.3% were Exp+. The majority of European (668/829, 80.6%) and South Asian (14/22, 63.6%) patients were Exp+, whereas the majority of those with African (30/37, 81.1%), East Asian (2/3,66.7%), and American Admixture (2/3, 66.7%) ancestry were Exp-. The percentage of females was significantly higher (151, 74.4%) in the Exp-cohort compared to the Exp+ (395, 57.2%; P<.001). The median (IQR) age at first keratoplasty of the Exp+ patients (68.2 [63.2–73.6] years) was older than the Exp-patients (61.3 [52.6–70.4] years; P<.001). The CTG18.1 repeat length of the largest expanded allele within the Exp+ group was inversely correlated with the age at first keratoplasty (r = -0.087 [95% CI: -0.162 to -0.012], P=.02). The ratio of biallelic to monoallelic expanded alleles was higher in the FECD cohort compared to an unaffected control group (P<.001), indicating that two Exp+ alleles increase disease penetrance compared to one expansion. We only identified potentially pathogenic variants (MAF <0.01; CADD >15) in FECD-associated genes in 13 (10.1%) Exp-individuals.
Conclusions and Relevance CTG18.1 expansions are present in most European and South Asian patients with FECD. Repeat length and zygosity status of CTG18.1 modify disease severity and penetrance. Known disease-associated genes account for only a minority of Exp-cases, with unknown risk factors determining disease in the rest of this subgroup. These data have important implications for the development of future FECD gene-targeted therapies.
Question How do demographics and genetic risk factors determine FECD disease risk and severity?
Findings This multi-center FECD cohort (n=894) study reveals TCF4 repeat expansions (CTG18.1) underlie disease in 77.3% of total cases, with longer repeats and biallelic expansion correlating with earlier keratoplasty and increased penetrance, respectively.
Female overrepresentation is driven by cases without CTG18.1 expansions, where missing heritability remains high.
Meaning Demographic factors and molecular diagnosis, including CTG18.1 repeat length and expanded allele dosage, are clinically relevant metrics that should inform future therapeutic strategies and clinical trial design.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by a UKRI Future Leader Fellowship MR/S031820/1 (AED), Moorfields Eye Charity GR000060, GR001395, GR001337 (AED) and Sight Research UK SAC 036 (AED), the Rosetrees Trust M784 (AED), Medical Research Council MR/X006271/1 (SL, AED), Fight for Sight 5171 / 5172 (MAC, AED) and The National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital National Health Service Foundation Trust and UCL Institute of Ophthalmology (AED, NC, SJT, KM, AJH, MEC, NP). LD, PS, and PL were supported by MH CZ-DRO-VFN64165, GACR 20-19278S, UNCE/24/MED/022 and SVV 2600631. NP is funded by a National Institute for Health Research (NIHR) AI Award (AI_AWARD02488). ASK is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, project number 527928847).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Committees of University College London (UCL) (22/EE/0090), Moorfields Eye Hospital (MEH) London (13/LO/1084), or the General University Hospital (GUH) Prague (151/11 S-IV) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
In this study we used patient identifiable information. For this reason raw data can not be made publicly available due to confidentiality considerations.
